3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
36
Nivolumab
16
Cyclophosphamide
12
atezolizumab
8
Docetaxel
8
Magnetic Resonance Spectroscopy
7
Paclitaxel
6
Everolimus
6
spartalizumab
5
fludarabine
5
durvalumab
5
Specimen Handling
5
Ipilimumab
5
cabozantinib
4
avelumab
4
Trastuzumab
4
Radiotherapy
4
Radiosurgery
4
Oxaliplatin
4
Leucovorin
4
temsirolimus
3
pazopanib
3
aldesleukin
3
Taxes
3
Sunitinib
3
Psychiatric Rehabilitation
3
Interleukin-2
3
Immune Checkpoint Inhibitors
3
Gemcitabine
3
Fluorouracil
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Blood Component Removal
×
Breast
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled